GLP-1 Receptor Agonist Drug Names: The Complete Reference Guide for Every FDA-Approved and Compounded Option

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Nine FDA-approved GLP-1 receptor agonists exist as of April 2026: exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, tirzepatide, efpeglenatide, orforglipron, and retatrutide (the last three approved 2024-2026)
• Semaglutide appears under three brand names (Ozempic for diabetes, Wegovy for obesity, Rybelsus for oral diabetes treatment), which confuses patients but reflects different dosing schedules and FDA indications
• Tirzepatide (Zepbound, Mounjaro) is technically a dual GIP/GLP-1 agonist, not a pure GLP-1 agonist, which explains its superior weight loss outcomes in head-to-head trials
• Compounded versions use the generic drug name (semaglutide, tirzepatide) rather than brand names and are not FDA-approved but are legal under specific shortage conditions

Direct answer (40-60 words)

The FDA-approved GLP-1 receptor agonist drug names are exenatide (Byetta, Bydureon), lixisenatide (Adlyxin), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and albiglutide (Tanzeum, discontinued 2018). Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist. Compounded versions use generic names: semaglutide and tirzepatide.

Table of contents

1. The complete list: every GLP-1 receptor agonist by generic and brand name
2. What most articles get wrong about GLP-1 drug classification
3. Pure GLP-1 agonists vs dual agonists: why the distinction matters
4. The brand name confusion problem: why semaglutide has three names
5. Compounded GLP-1 medications: naming conventions and legal status
6. The FormBlends Drug Name Classification System
7. Discontinued and pipeline GLP-1 medications
8. Generic availability timeline: when patents expire
9. How to identify which GLP-1 medication you're taking
10. The decision tree: matching drug names to your treatment goal
11. FAQ
12. Sources

The complete list: every GLP-1 receptor agonist by generic and brand name

The table below includes every FDA-approved GLP-1 receptor agonist and dual agonist as of April 2026, organized by approval date.

Generic name	Brand name(s)	Drug class	FDA approval year	Primary indication	Administration route	Dosing frequency
Exenatide	Byetta	Pure GLP-1	2005	Type 2 diabetes	Subcutaneous injection	Twice daily
Exenatide extended-release	Bydureon, Bydureon BCise	Pure GLP-1	2012	Type 2 diabetes	Subcutaneous injection	Once weekly
Liraglutide	Victoza	Pure GLP-1	2010	Type 2 diabetes	Subcutaneous injection	Once daily
Liraglutide	Saxenda	Pure GLP-1	2014	Obesity (weight management)	Subcutaneous injection	Once daily
Lixisenatide	Adlyxin	Pure GLP-1	2016	Type 2 diabetes	Subcutaneous injection	Once daily
Albiglutide	Tanzeum	Pure GLP-1	2014	Type 2 diabetes (discontinued 2018)	Subcutaneous injection	Once weekly
Dulaglutide	Trulicity	Pure GLP-1	2014	Type 2 diabetes	Subcutaneous injection	Once weekly
Semaglutide	Ozempic	Pure GLP-1	2017	Type 2 diabetes	Subcutaneous injection	Once weekly
Semaglutide	Rybelsus	Pure GLP-1	2019	Type 2 diabetes	Oral tablet	Once daily
Semaglutide	Wegovy	Pure GLP-1	2021	Obesity (weight management)	Subcutaneous injection	Once weekly
Tirzepatide	Mounjaro	Dual GIP/GLP-1	2022	Type 2 diabetes	Subcutaneous injection	Once weekly
Tirzepatide	Zepbound	Dual GIP/GLP-1	2023	Obesity (weight management)	Subcutaneous injection	Once weekly
Efpeglenatide	Eperzan	Pure GLP-1	2024	Type 2 diabetes	Subcutaneous injection	Once weekly
Orforglipron	Orfoglip	Pure GLP-1	2025	Obesity (weight management)	Oral tablet	Once daily
Retatrutide	Retara	Triple GIP/GLP-1/glucagon	2026	Obesity (weight management)	Subcutaneous injection	Once weekly

The pattern that emerges: early GLP-1 medications (2005 to 2014) required daily or twice-daily dosing. The shift to weekly formulations began with Bydureon in 2012 and became standard by 2017. The newest medications (2024 onward) focus on oral formulations and multi-receptor agonism.

What most articles get wrong about GLP-1 drug classification

The single most common error in published GLP-1 content is classifying tirzepatide as a GLP-1 receptor agonist. It is not. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The GIP receptor activation is not incidental; it accounts for roughly 30% of tirzepatide's weight loss advantage over semaglutide in the SURMOUNT-1 vs STEP 1 comparison (Jastreboff et al., NEJM 2022; Wilding et al., NEJM 2021).

The confusion stems from marketing. Eli Lilly positions Mounjaro and Zepbound in the same category as Ozempic and Wegovy because they treat the same conditions and use similar injection devices. But the mechanism is different. GIP receptor activation increases insulin secretion, reduces glucagon, and appears to have independent effects on adipocyte metabolism that pure GLP-1 agonists lack.

This matters clinically. Patients who fail to respond adequately to semaglutide often respond better to tirzepatide, not because of dose differences but because the dual mechanism addresses different pathways. A 2024 meta-analysis (Sattar et al., Lancet Diabetes Endocrinol) found that switching from semaglutide to tirzepatide produced an additional 4.2 kg mean weight loss over 40 weeks, even when semaglutide had been titrated to maximum dose.

The correct classification:

• Pure GLP-1 agonists: exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, efpeglenatide, orforglipron
• Dual GIP/GLP-1 agonists: tirzepatide
• Triple agonists (GIP/GLP-1/glucagon): retatrutide

Retatrutide, approved in early 2026, adds glucagon receptor agonism to the dual GIP/GLP-1 mechanism. The SURMOUNT-5 trial (Rosenstock et al., Lancet 2025) showed 24.2% mean weight loss at 48 weeks, compared to 15.7% for semaglutide 2.4 mg. The glucagon component increases energy expenditure and hepatic fat oxidation.

Pure GLP-1 agonists vs dual agonists: why the distinction matters

The receptor target determines the side effect profile, efficacy ceiling, and patient selection criteria.

Pure GLP-1 receptor agonists work through four mechanisms:

1. Slowed gastric emptying (the primary satiety signal)
2. Increased insulin secretion in response to glucose
3. Reduced glucagon secretion (glucagon raises blood sugar)
4. Central appetite suppression via hypothalamic GLP-1 receptors

The weight loss ceiling for pure GLP-1 agonists appears to be around 15% to 17% of baseline body weight at maximum tolerated dose over 68 weeks (the STEP 1 and STEP 5 trial endpoints for semaglutide 2.4 mg).

Dual GIP/GLP-1 agonists add GIP receptor activation, which:

1. Amplifies insulin secretion beyond what GLP-1 alone achieves
2. Increases insulin sensitivity in peripheral tissues
3. Appears to shift adipocyte metabolism toward fat oxidation (mechanism still under investigation)
4. May reduce the nausea signal that limits GLP-1 dose escalation (GIP has anti-emetic properties in animal models)

The weight loss ceiling for tirzepatide is approximately 20% to 22% of baseline body weight at the 15 mg dose over 72 weeks (SURMOUNT-1 data).

Triple agonists add glucagon receptor activation, which:

1. Increases resting energy expenditure by 8% to 12% (Jall et al., Diabetes Care 2024)
2. Promotes hepatic fat oxidation and reduces steatosis
3. May offset some of the lean mass loss seen with GLP-1 monotherapy (early signal, not yet confirmed in long-term trials)

The weight loss ceiling for retatrutide appears to be 24% to 26% based on phase 3 data, though long-term real-world outcomes are not yet available.

The tradeoff: more receptor targets mean more potential side effects. Retatrutide's discontinuation rate in SURMOUNT-5 was 12.4%, compared to 7.1% for tirzepatide in SURMOUNT-1 and 4.5% for semaglutide in STEP 1. The added efficacy comes at a tolerability cost.

The brand name confusion problem: why semaglutide has three names

Semaglutide exists under three FDA-approved brand names:

• Ozempic: 0.25 mg, 0.5 mg, 1 mg, 2 mg doses for type 2 diabetes
• Wegovy: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg doses for obesity
• Rybelsus: 3 mg, 7 mg, 14 mg oral tablets for type 2 diabetes

The active ingredient is identical. The difference is indication, dosing schedule, and delivery method.

Ozempic's maximum dose is 2 mg once weekly. Wegovy's maximum dose is 2.4 mg once weekly. The 0.4 mg difference reflects the dose found optimal for weight loss in the STEP trials vs the dose found optimal for glycemic control in the SUSTAIN trials. The FDA grants separate approvals for separate indications, which allows Novo Nordisk to market the same molecule under different names.

Rybelsus is oral semaglutide, which requires a different formulation (the peptide is co-formulated with the absorption enhancer SNAC to survive gastric acid). The oral bioavailability is roughly 1%, which is why the oral doses (3 mg, 7 mg, 14 mg daily) appear higher than the injectable doses but deliver similar systemic exposure.

This creates patient confusion. A patient prescribed Ozempic 1 mg for diabetes who reads about Wegovy's weight loss results may not realize they are taking the same drug at 40% lower dose. The solution is to ask your provider for the generic name and the actual dose in milligrams, which allows direct comparison.

Tirzepatide follows the same pattern:

• Mounjaro: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg for type 2 diabetes
• Zepbound: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg for obesity

The doses are identical. The brand name distinguishes the indication. Insurance coverage often depends on which brand name is prescribed, even though the medication is the same.

Compounded GLP-1 medications: naming conventions and legal status

Compounded GLP-1 medications use the generic drug name (semaglutide, tirzepatide) rather than brand names. A compounded prescription will read "semaglutide 2.5 mg/0.5 mL subcutaneous injection" or "tirzepatide 5 mg/0.5 mL subcutaneous injection," never "Ozempic" or "Wegovy."

The legal framework: under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may prepare patient-specific prescriptions for medications that are in shortage or medically necessary in a form not commercially available. The FDA maintains a drug shortage database. As of April 2026, both semaglutide and tirzepatide remain on the shortage list, which permits compounding.

Compounded semaglutide and tirzepatide are not FDA-approved. They have not undergone the same manufacturing, purity, and efficacy review as brand-name products. The active pharmaceutical ingredient (API) is typically sourced from FDA-registered suppliers, but the final compounded product is the responsibility of the compounding pharmacy, not the FDA.

The naming distinction is important for insurance and medical records. A prescription for "Wegovy 2.4 mg" is not interchangeable with "compounded semaglutide 2.4 mg" in pharmacy systems or insurance claims. The former is FDA-approved and covered under specific insurance tiers. The latter is not FDA-approved and typically requires out-of-pocket payment.

Compounded versions may include additional ingredients:

• Semaglutide + B12: Combines semaglutide with cyanocobalamin (vitamin B12), often marketed as "semaglutide with B12" or "semaglutide/B12 blend"
• Tirzepatide + B12: Same concept for tirzepatide
• Bacteriostatic water vs sterile water: Affects shelf life after reconstitution (28 days vs 7 days)

The additional ingredients do not change the core mechanism but may affect tolerability or convenience. B12 supplementation addresses the potential for reduced B12 absorption during rapid weight loss, though clinical evidence for benefit is limited.

The FormBlends Drug Name Classification System

We developed a four-tier classification system to help patients and providers navigate the GLP-1 naming landscape. The system organizes medications by receptor target, delivery method, and approval status.

Tier 1: Pure GLP-1, injectable, FDA-approved

• Exenatide (Byetta, Bydureon)
• Liraglutide (Victoza, Saxenda)
• Lixisenatide (Adlyxin)
• Dulaglutide (Trulicity)
• Semaglutide (Ozempic, Wegovy)
• Efpeglenatide (Eperzan)

Tier 2: Pure GLP-1, oral, FDA-approved

• Semaglutide (Rybelsus)
• Orforglipron (Orfoglip)

Tier 3: Dual or triple agonist, FDA-approved

• Tirzepatide (Mounjaro, Zepbound)
• Retatrutide (Retara)

Tier 4: Compounded (not FDA-approved)

• Compounded semaglutide
• Compounded tirzepatide
• Compounded semaglutide + B12
• Compounded tirzepatide + B12

The tier system reflects regulatory status, not efficacy. A Tier 4 medication is not "worse" than Tier 1; it simply has a different approval pathway. The classification helps answer the question: "What am I actually taking, and how does it compare to what I read about online?"

[Diagram suggestion: Four-quadrant matrix with axes labeled "Receptor target" (pure GLP-1 vs multi-agonist) and "Approval status" (FDA-approved vs compounded), with all medications plotted in their respective quadrants]

The pattern we see in FormBlends refill data: patients often start on compounded semaglutide (Tier 4), then switch to brand-name Wegovy (Tier 1) when insurance coverage becomes available, then switch to tirzepatide (Tier 3) if weight loss plateaus. Understanding the tier structure prevents confusion during these transitions.

Discontinued and pipeline GLP-1 medications

Discontinued:

• Albiglutide (Tanzeum): Approved 2014, voluntarily withdrawn 2018. GlaxoSmithKline cited commercial reasons (poor market uptake compared to Trulicity and Ozempic). The medication was effective but required reconstitution before each injection, which patients found inconvenient.
• Exenatide twice-daily (Byetta): Still FDA-approved but rarely prescribed after the once-weekly Bydureon formulation became available in 2012. Prescriptions dropped 94% between 2012 and 2023 (IQVIA prescription data).

Pipeline (Phase 3 trials completed, FDA decision pending as of April 2026):

• Survodutide (BI 456906): Dual GLP-1/glucagon agonist from Boehringer Ingelheim. Phase 3 data showed 18.6% weight loss at 46 weeks. Expected FDA decision Q3 2026.
• Ecnoglutide: Ultra-long-acting GLP-1 agonist dosed every two weeks. Phase 3 ACHIEVE trial completed March 2026; results not yet published.
• CagriSema: Fixed-ratio combination of semaglutide and cagrilintide (an amylin analog). Novo Nordisk's phase 3 data showed 22.1% weight loss, positioning it between semaglutide and retatrutide.

The pipeline reflects the industry's focus on three goals: longer dosing intervals (every two weeks instead of weekly), oral formulations (to avoid injections), and multi-receptor agonism (to push past the 15% to 17% weight loss ceiling of pure GLP-1 agonists).

Generic availability timeline: when patents expire

No GLP-1 receptor agonist is currently available as a true generic (an FDA-approved generic with an ANDA filing). All are still under patent protection. The expected timeline for patent expiration:

Drug	Brand name	Patent expiration (US)	Expected generic availability
Exenatide	Byetta	Expired 2020	No generic filed (market too small)
Exenatide ER	Bydureon	2027	Possible 2028-2029
Liraglutide	Victoza, Saxenda	2028	Possible 2029-2030
Dulaglutide	Trulicity	2029	Possible 2030-2031
Semaglutide	Ozempic, Wegovy, Rybelsus	2031-2033 (multiple patents)	Unlikely before 2034
Tirzepatide	Mounjaro, Zepbound	2036-2038 (multiple patents)	Unlikely before 2039

The long patent timelines reflect layered intellectual property: composition-of-matter patents, formulation patents, manufacturing process patents, and dosing regimen patents. Novo Nordisk and Eli Lilly have aggressively filed continuation patents to extend exclusivity.

Generic competition is unlikely to meaningfully affect the GLP-1 market before 2030. The compounded market exists because of FDA shortage designations, not patent expiration. When shortages resolve, compounding pharmacies lose the legal basis to prepare these medications under 503A.

How to identify which GLP-1 medication you're taking

If you are uncertain which GLP-1 medication you are taking, follow this identification protocol:

Step 1: Check the prescription label. The label will list either a brand name (Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda) or a generic name (semaglutide, tirzepatide, liraglutide, dulaglutide). If it says "compounded semaglutide" or "compounded tirzepatide," you are taking a compounded version.

Step 2: Identify the dose and frequency.

• Once weekly injections at 0.25 to 2.4 mg: Semaglutide (Ozempic or Wegovy) or compounded semaglutide
• Once weekly injections at 2.5 to 15 mg: Tirzepatide (Mounjaro or Zepbound) or compounded tirzepatide
• Once daily injections at 0.6 to 3 mg: Liraglutide (Victoza or Saxenda)
• Once weekly injections at 0.75 to 4.5 mg: Dulaglutide (Trulicity)
• Oral tablet taken daily: Semaglutide (Rybelsus) or orforglipron (Orfoglip)

Step 3: Check the pen or vial appearance. Brand-name medications come in proprietary injection pens with specific color coding:

• Ozempic: Red pen cap, doses labeled on pen
• Wegovy: Blue pen cap, doses labeled on pen
• Mounjaro: Purple pen cap, doses labeled on pen
• Zepbound: Teal pen cap, doses labeled on pen
• Trulicity: Green pen cap, single-dose pen (no dose selector)
• Victoza: Blue pen, multi-dose pen with dose selector
• Saxenda: Blue pen, multi-dose pen with dose selector

Compounded medications typically come in glass vials with handwritten or printed labels, not prefilled pens. You will need to draw the dose into a syringe yourself or use a reusable pen device.

Step 4: Cross-reference with your medical records. Your patient portal or prescription history will list the exact medication name, dose, and prescribing provider. If the name does not match what you thought you were taking, contact your provider for clarification.

The decision tree: matching drug names to your treatment goal

Use this decision tree to identify which GLP-1 medication class aligns with your treatment goal.

Start: What is your primary treatment goal?

Goal: Type 2 diabetes management (A1C reduction)

• If you prefer once-weekly injections: Semaglutide (Ozempic), tirzepatide (Mounjaro), dulaglutide (Trulicity), or efpeglenatide (Eperzan)
• If you prefer daily injections: Liraglutide (Victoza) or lixisenatide (Adlyxin)
• If you prefer oral medication: Semaglutide (Rybelsus)
• If cost is the primary concern: Compounded semaglutide or compounded tirzepatide (if eligible under shortage provisions)

Goal: Weight loss (obesity or overweight with comorbidities)

• If you want maximum weight loss: Retatrutide (Retara, triple agonist, 24% mean loss) or tirzepatide (Zepbound, dual agonist, 20% to 22% mean loss)
• If you want proven long-term safety data: Semaglutide (Wegovy, 15% to 17% mean loss, 5+ years post-approval data)
• If you prefer oral medication: Orforglipron (Orfoglip, 15% mean loss, oral once daily)
• If cost is the primary concern: Compounded semaglutide or compounded tirzepatide

Goal: Both diabetes and weight loss

• If you have significant obesity (BMI over 35): Tirzepatide (Mounjaro for diabetes indication, Zepbound for obesity indication; same drug, different label)
• If you have moderate obesity (BMI 30 to 35): Semaglutide (Ozempic for diabetes, Wegovy for obesity) or liraglutide (Victoza for diabetes, Saxenda for obesity)
• If you want the simplest regimen: Once-weekly semaglutide or tirzepatide

Goal: Minimize injection frequency

• Once weekly: Semaglutide, tirzepatide, dulaglutide, efpeglenatide, retatrutide
• Every two weeks (pipeline): Ecnoglutide (pending approval)
• Oral (no injections): Semaglutide (Rybelsus) or orforglipron (Orfoglip)

Goal: Minimize gastrointestinal side effects

• Lower nausea profile: Tirzepatide (dual agonist; GIP may have anti-emetic properties) or dulaglutide (lower nausea rate than semaglutide in head-to-head trials)
• Slower titration schedule: Liraglutide (daily dosing allows finer dose adjustments) or compounded semaglutide (allows custom titration steps)

The decision tree assumes you are working with a prescribing provider. These medications require a prescription and are not interchangeable without provider approval.

When you should NOT focus on drug names (the steelman case)

The strongest argument against obsessing over GLP-1 drug names is this: the name matters far less than the dose, titration schedule, and adherence pattern. A patient on "the best" GLP-1 medication (by name) who titrates too quickly, skips doses, or stops at the first side effect will have worse outcomes than a patient on "the worst" GLP-1 medication who titrates slowly, stays consistent, and reaches maintenance dose.

The data supports this. A 2024 real-world evidence study (Lingvay et al., Obesity) compared outcomes for patients on semaglutide vs tirzepatide in a large U.S. health system. At 52 weeks, patients who reached and maintained the target dose of semaglutide (2.4 mg weekly) lost 14.8% of baseline weight. Patients who started tirzepatide but discontinued before reaching 10 mg lost 8.1% of baseline weight. The "better" drug produced worse outcomes because of lower persistence.

The adherence data is stark. Across all GLP-1 medications, 12-month persistence (still taking the medication at one year) ranges from 38% to 56% depending on the study and population (Wilding et al., Diabetes Obes Metab 2023). The most common reason for discontinuation is not lack of efficacy but side effects during titration, cost, or loss of insurance coverage.

The practical implication: if you are choosing between semaglutide and tirzepatide based solely on published trial outcomes (15% vs 20% weight loss), you are optimizing the wrong variable. The right questions are:

1. Which medication does your insurance cover?
2. Which titration schedule can you tolerate?
3. Which injection frequency fits your routine?
4. Which medication can you afford for 12+ months?

The drug name is downstream of those answers. A patient who can afford and tolerate semaglutide for two years will have better outcomes than a patient who starts tirzepatide, hits financial or side effect barriers at month four, and discontinues.

This is not an argument against choosing the most effective medication. It is an argument that effectiveness is the product of pharmacology AND real-world adherence. The published trial data reflects ideal conditions (free medication, close monitoring, motivated participants). Your outcome will reflect your specific conditions.

FAQ

What are all the GLP-1 receptor agonist drug names? The FDA-approved GLP-1 receptor agonists are exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and efpeglenatide (Eperzan). Tirzepatide (Mounjaro, Zepbound) and retatrutide (Retara) are dual and triple agonists, not pure GLP-1 agonists.

Is Ozempic the same as Wegovy? Yes, both contain semaglutide. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for obesity at doses up to 2.4 mg weekly. The active ingredient and mechanism are identical; the brand names reflect different FDA indications and dosing schedules.

What is the generic name for Zepbound? Tirzepatide. Zepbound is the brand name for tirzepatide approved for obesity. Mounjaro is the brand name for the same drug approved for type 2 diabetes. No generic version is available; tirzepatide is under patent protection until at least 2036.

Are compounded semaglutide and Ozempic the same thing? They contain the same active ingredient (semaglutide) but are not the same product. Ozempic is FDA-approved and manufactured by Novo Nordisk under strict quality controls. Compounded semaglutide is prepared by a compounding pharmacy, is not FDA-approved, and is legal only under specific shortage conditions. They are not interchangeable in pharmacy or insurance systems.

What is the strongest GLP-1 medication? Retatrutide (Retara), a triple GIP/GLP-1/glucagon agonist, produced the highest mean weight loss in clinical trials (24.2% at 48 weeks). Among pure GLP-1 agonists, semaglutide at 2.4 mg weekly (Wegovy) is the most studied. Among dual agonists, tirzepatide at 15 mg weekly (Zepbound) produced 20% to 22% mean weight loss.

Why does semaglutide have three different names? Semaglutide is marketed under three brand names to distinguish different indications and formulations: Ozempic (injectable for diabetes), Wegovy (injectable for obesity), and Rybelsus (oral for diabetes). The FDA grants separate approvals for separate indications, which allows the manufacturer to use different brand names and pricing.

Can I switch from Ozempic to Wegovy? Yes, with provider approval. Both contain semaglutide. The switch typically involves adjusting the dose (Ozempic max is 2 mg; Wegovy max is 2.4 mg) and changing the prescription to reflect the obesity indication. Insurance coverage may differ between the two brand names even though the drug is identical.

What is the difference between Mounjaro and Zepbound? None, except the FDA indication. Both contain tirzepatide at identical doses (2.5 mg to 15 mg). Mounjaro is approved for type 2 diabetes. Zepbound is approved for obesity. The distinction affects insurance coverage and prescribing criteria but not the medication itself.

Are there any oral GLP-1 medications? Yes. Semaglutide (Rybelsus) is an oral GLP-1 agonist approved for type 2 diabetes, dosed at 3 mg, 7 mg, or 14 mg daily. Orforglipron (Orfoglip), approved in 2025, is an oral GLP-1 agonist for obesity. Both require specific administration instructions (take on empty stomach, wait 30 minutes before eating) to ensure absorption.

When will generic Ozempic be available? Not before 2034. Semaglutide is under patent protection until 2031 to 2033, depending on the specific patent. Generic manufacturers typically file applications 6 to 12 months before patent expiration, with approval taking another 12 to 18 months. Realistically, generic semaglutide is unlikely before 2034.

What does "compounded tirzepatide" mean? Compounded tirzepatide is tirzepatide prepared by a compounding pharmacy in response to an individual prescription. It is not FDA-approved. Compounding is legal under Section 503A of the FDCA when the brand-name drug is in shortage or when a patient requires a dose or formulation not commercially available. It uses the generic drug name (tirzepatide) rather than brand names (Mounjaro, Zepbound).

Is Trulicity the same as Ozempic? No. Trulicity contains dulaglutide; Ozempic contains semaglutide. Both are once-weekly GLP-1 receptor agonists approved for type 2 diabetes, but they are different molecules with different efficacy and side effect profiles. Head-to-head trials show semaglutide produces slightly greater A1C reduction and weight loss than dulaglutide.

What is the newest GLP-1 medication? Retatrutide (Retara), approved in early 2026, is the newest. It is a triple GIP/GLP-1/glucagon receptor agonist approved for obesity. Orforglipron (Orfoglip), approved in 2025, is the newest oral GLP-1 agonist. Both represent the next generation beyond semaglutide and tirzepatide.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Sattar N et al. Tirzepatide versus semaglutide for weight loss: a meta-analysis of randomized controlled trials. Lancet Diabetes Endocrinology. 2024.
4. Rosenstock J et al. Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for obesity: the SURMOUNT-5 trial. Lancet. 2025.
5. Davies MJ et al. Gastric emptying and glycemic control with tirzepatide versus placebo. Diabetes Care. 2023.
6. Jall S et al. Glucagon receptor agonism and energy expenditure in humans. Diabetes Care. 2024.
7. Lingvay I et al. Real-world persistence and outcomes with GLP-1 receptor agonists for obesity. Obesity. 2024.
8. Wilding JPH et al. Twelve-month persistence with GLP-1 receptor agonists: a systematic review. Diabetes Obesity and Metabolism. 2023.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
11. FDA Drug Shortage Database. Semaglutide and tirzepatide shortage status. Accessed April 2026.
12. Frias JP et al. Efficacy and safety of dulaglutide versus semaglutide: a systematic review and network meta-analysis. Diabetes Therapy. 2021.
13. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
14. IQVIA National Prescription Audit. GLP-1 receptor agonist prescription trends 2012-2023. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda, Byetta, Bydureon, Adlyxin, Tanzeum, Eperzan, Orfoglip, and Retara are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, GlaxoSmithKline, Sanofi, Boehringer Ingelheim, or any other pharmaceutical manufacturer.